Investment Overview - Novartis Latest M&A Deal Speaks to Pipeline Pressure A few days ago (March 20th), Swiss Pharmaceuticals giant Novartis (NVS) announced it would pay $2bn up front (the deal may rise to $3bn if milestones are met) to acquire Pikavation Therapeutics, a wholly owned subsidiary of Synnovation, a privately owned Biotech headquartered in Delaware. The clue is in the name - Pikavation is developing SNV4818, a pan-mutant‑selective PI3Kα inhibitor, "exploring a next-generation approach for the t ...